Trial · NCT04157335
Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)
NCT04157335, Phase 3, Terminated, AstraZeneca; results first posted 2026-02-19
3 sourcestrials-2026-11-12-0.5.0
Download JSON
Cite this record
ConductScience Library. Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID). Trials, record NCT04157335. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04157335
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)
- NCT number
- NCT04157335
- Status
- Terminated
- Phases
- Phase 3
- Enrollment
- 295 participants, actual
- Lead sponsor
- AstraZeneca
- Conditions
- Nasal Polyposis, Eosinophilic Chronic Rhinosinusitis
- Interventions
- Benralizumab 30 mg, Matched placebo
- First posted
- 2019-11-08
- Last updated
- 2026-02-19
- Other registries' IDs
- eudract:2021-000267-72
- Results first posted
- 2026-02-19
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change From Baseline in Endoscopic Total Nasal Polyp Score (NPS) at Week 56 | Baseline to Week 56 | The total nasal polyp score (NPS) is the sum of the right and left nostril scores (maximum of 8), as evaluated by nasal endoscopy. Higher scores indicate greater symptom severity. The left and right score will be based on a central read with a scale from 0 to 4. Each nasal endoscopy is evaluated by two independent physician reviewers. |
| Primary | Change From Baseline in Mean Nasal Blockage Score (NBS) at Week 56. | Baseline to week 56 | The NBS is an item in the NPSD. Patients were asked to rate the severity of their worst nasal blockage over the past 24 hours using the following response options: 0 - none; 1 - mild; 2 - moderate; 3 - severe. Higher scores indicate greater symptom severity. The NBS and the changes from baseline were summarised every two weeks (bi-weekly). Baseline was the average of daily responses from Day -13 to Day 1. Bi-weekly mean were calculated if at least 8 days in each 14-day period had evaluable data; otherwise, the biweekly mean was set to missing. |
| Secondary | Change From Baseline in Difficulty With Sense of Smell (DSS) Score at Week 56. | Baseline to Week 56 | The DSS is an item in the NPSD. Patients were asked to rate the severity of their worst difficulty with sense of smell over the past 24 hours using the following response options: 0-none; 1-mild; 2-moderate; 3-severe. Higher scores indicate greater symptom severity. The DSS and the changes from baseline were summarised every two weeks (bi-weekly). Baseline was the average of daily responses from Day -13 to Day 1. Bi-weekly mean of DSS was calculated if at least 8 days in each 14-day period have evaluable data; otherwise the bi-weekly mean was set to missing. |
| Secondary | Sinus Opacification by CT Scan at Week 56. | Baseline to Week 56 | Change from baseline in Lund- Mackay score (LMS). The Lund-Mackay score scoring system is used to provide a quantitative assessment of nasal sinuses on sinus CT scans. Based on the sinus CT images, the five sinuses (maxillary, anterior ethmoid, posterior ethmoid, sphenoid and frontal) on each site are score by central radiologist as follows: (0-Normal; 1-Partial Opacification; 2-Total Opacification). The osteomeatal complex is scored for right and left sides (0 - Not occluded; 2- Occluded). The total score ranges from 0 to 24 (higher scores indicate poorer outcomes). |
| Secondary | Disease Specific Health-related Quality of Life (HRQoL): Change From Baseline in SinoNasal Outcome Test (SNOT-22) Score at Week 56. | Baseline to Week 56 | SinoNasal Outcome Test 22 scores are participant-reported and assess physical problems, functional limitations and emotional consequences of SinoNasal conditions. Patient-reported symptom severity and symptom impact over the past 2 weeks are captured via a 6-point scale (0-No Problem to 5-Problem as bad as it can be). The total score is the sum of item scores and has a range from 0 to 110 (higher scores indicate poorer outcomes). |
| Secondary | Time to First Nasal Polyp Surgery | Baseline to Week 56 | Time to the first surgery for CRSwNP= Start date of the first surgery for CRSwNP - date of randomisation + 1 |
| Secondary | Time to First SCS Course for CRSwNP | Baseline to Week 56 | Time to the first SCS use for CRSwNP = Start date of the first SCS use for CRSwNP - date of randomisation + 1 |
| Secondary | Time to First NP Surgery and/or SCS Use for CRSwNP | Baseline to Week 56 | Time to first surgery and/or SCS use for CRSwNP = earlier date of (start date of first surgery for CRSwNP, start date of first SCS use for CRSwNP) - date of randomisation + 1 |
| Secondary | Change From Baseline in Bi-weekly Mean Nasal Polyps Symptom Diary Total Symptom Score at Week 56. | Baseline to Week 56 | The participant completed the nasal polyposis symptom diary each morning throughout the study. The participant was asked to consider their experience with nasal polyposis/nasal polyps over the past 24 hours when responding to each question. Participants were asked to report their experience with nasal polyposis symptoms (nasal blockage, nasal congestion, runny nose, postnasal drip (mucus drainage down the throat), headache, facial pain, facial pressure, difficulty with sense of smell). Participants reported the severity of each symptom and symptom impact at its worst using a 4-point verbal rating scale (0-None to 3-Severe). A total symptom score (range from 0 to 24) was calculated by taking the sum of the 8 equally weighted symptom items. Higher scores indicate greater symptom severity. |
| Secondary | Percentage of Participants With Surgery and/or Use SCS for CRSwNP | Baseline to Week 56 | Nasal polyps surgery is defined as any procedure involving instruments resulting in incision and removal of tissue (e.g. polypectomy, endoscopic sinus surgery). An SCS course can be considered as a new course if the start date is preceded by at least 7 days after the end date of the last SCS course for CRSwNP (i.e. start date of the new course - end date of the last course \> 7) |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline in Endoscopic Total Nasal Polyp Score (NPS) at Week 56 | Baseline to Week 56 | Primary full analysis set (All CRSwNP participants with asthma who were randomized and received any IP. N=139 in treatment group and N=135 in placebo). The analysis included all participants with baseline and at least one evaluable post-baseline assessment and all the participants with a baseline assessment who are rescued by surgery and/or SCS use for CRSwNP. | Score | MEAN |
| PRIMARY | Change From Baseline in Mean Nasal Blockage Score (NBS) at Week 56. | Baseline to week 56 | Primary full analysis set (All CRSwNP participants with asthma who were randomized and received any IP. N=139 in treatment group and N=135 in placebo). The analysis included all participants with baseline and at least one evaluable post-baseline assessment and all the participants with a baseline assessment who are rescued by surgery and/or SCS use for CRSwNP. | Score | MEAN |
| SECONDARY | Change From Baseline in Difficulty With Sense of Smell (DSS) Score at Week 56. | Baseline to Week 56 | Primary full analysis set (All CRSwNP participants with asthma who were randomized and received any IP. N=139 in treatment group and N=135 in placebo). The analysis included all participants with baseline and at least one evaluable post-baseline assessment and all the participants with a baseline assessment who are rescued by surgery and/or SCS use for CRSwNP. | Score | MEAN |
| SECONDARY | Sinus Opacification by CT Scan at Week 56. | Baseline to Week 56 | Primary full analysis set (All CRSwNP participants with asthma who were randomized and received any IP. N=139 in treatment group and N=135 in placebo). The analysis included all participants with baseline and at least one evaluable post-baseline assessment and all the participants with a baseline assessment who are rescued by surgery and/or SCS use for CRSwNP. | Score | MEAN |
| SECONDARY | Disease Specific Health-related Quality of Life (HRQoL): Change From Baseline in SinoNasal Outcome Test (SNOT-22) Score at Week 56. | Baseline to Week 56 | Primary full analysis set (All CRSwNP participants with asthma who were randomized and received any IP. N=139 in treatment group and N=135 in placebo). The analysis included all participants with baseline and at least one evaluable post-baseline assessment and all the participants with a baseline assessment who are rescued by surgery and/or SCS use for CRSwNP. | Score | MEAN |
| SECONDARY | Time to First Nasal Polyp Surgery | Baseline to Week 56 | Primary full analysis set (All CRSwNP participants with asthma who were randomized and received any IP. N=139 in treatment group and N=135 in placebo). | Months | MEDIAN |
| SECONDARY | Time to First SCS Course for CRSwNP | Baseline to Week 56 | Primary full analysis set (All CRSwNP participants with asthma who were randomized and received any IP. N=139 in treatment group and N=135 in placebo). | Months | MEDIAN |
| SECONDARY | Time to First NP Surgery and/or SCS Use for CRSwNP | Baseline to Week 56 | Primary full analysis set (All CRSwNP participants with asthma who were randomized and received any IP. N=139 in treatment group and N=135 in placebo). | Months | MEDIAN |
| SECONDARY | Change From Baseline in Bi-weekly Mean Nasal Polyps Symptom Diary Total Symptom Score at Week 56. | Baseline to Week 56 | Primary full analysis set (All CRSwNP participants with asthma who were randomized and received any IP. N=139 in treatment group and N=135 in placebo). The analysis included all participants with baseline and at least one evaluable post-baseline assessment and all the participants with a baseline assessment who are rescued by surgery and/or SCS use for CRSwNP. | Score | MEAN |
| SECONDARY | Percentage of Participants With Surgery and/or Use SCS for CRSwNP | Baseline to Week 56 | Primary full analysis set (All CRSwNP participants with asthma who were randomized and received any IP. N=139 in treatment group and N=135 in placebo). | Participants | COUNT_OF_PARTICIPANTS |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 outcomesResults by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Endoscopic Total Nasal Polyp Score (NPS) at Week 56 | Double Blind Benralizumab | -0.3 | Standard Deviation 1.6 | Score | |
| Change From Baseline in Endoscopic Total Nasal Polyp Score (NPS) at Week 56 | Double Blind Placebo | -0.1 | Standard Deviation 1.3 | Score | |
| Change From Baseline in Mean Nasal Blockage Score (NBS) at Week 56. | Double Blind Benralizumab | -0.64 | Standard Deviation 0.98 | Score | |
| Change From Baseline in Mean Nasal Blockage Score (NBS) at Week 56. | Double Blind Placebo | -0.45 | Standard Deviation 0.90 | Score | |
| Change From Baseline in Difficulty With Sense of Smell (DSS) Score at Week 56. | Double Blind Benralizumab | -0.26 | Standard Deviation 0.78 | Score | |
| Change From Baseline in Difficulty With Sense of Smell (DSS) Score at Week 56. | Double Blind Placebo | -0.05 | Standard Deviation 0.56 | Score | |
| Sinus Opacification by CT Scan at Week 56. | Double Blind Benralizumab | -1.3 | Standard Deviation 3.4 | Score | |
| Sinus Opacification by CT Scan at Week 56. | Double Blind Placebo | -0.7 | Standard Deviation 3.5 | Score | |
| Disease Specific Health-related Quality of Life (HRQoL): Change From Baseline in SinoNasal Outcome Test (SNOT-22) Score at Week 56. | Double Blind Benralizumab | -18.0 | Standard Error 29.6 | Score | |
| Disease Specific Health-related Quality of Life (HRQoL): Change From Baseline in SinoNasal Outcome Test (SNOT-22) Score at Week 56. | Double Blind Placebo | -15.2 | Standard Error 26.6 | Score |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 results by groupParticipant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Double-Blind Period | STARTED | Double Blind Benralizumab | 144 | |
| Double-Blind Period | STARTED | Double Blind Placebo | 143 | |
| Double-Blind Period | COMPLETED | Double Blind Benralizumab | 129 | |
| Double-Blind Period | COMPLETED | Double Blind Placebo | 130 | |
| Double-Blind Period | NOT COMPLETED | Double Blind Benralizumab | 15 | |
| Double-Blind Period | NOT COMPLETED | Double Blind Placebo | 13 | |
| Open-Label Extension Period | STARTED | Double Blind Benralizumab | 122 | |
| Open-Label Extension Period | STARTED | Double Blind Placebo | 125 | |
| Open-Label Extension Period | COMPLETED | Double Blind Benralizumab | 80 | |
| Open-Label Extension Period | COMPLETED | Double Blind Placebo | 86 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events184
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | COVID-19 | Infections and infestations | Double Blind Benralizumab | 22 | 144 | 23 |
| other | COVID-19 | Infections and infestations | Double Blind Placebo | 16 | 143 | 16 |
| other | COVID-19 | Infections and infestations | Double Blind Benralizumab First, Then Open Label Benralizumab | 9 | 122 | 9 |
| other | COVID-19 | Infections and infestations | Double Blind Placebo First, Then Open Label Benralizumab | 7 | 125 | 7 |
| other | Influenza | Infections and infestations | Double Blind Benralizumab | 1 | 144 | 1 |
| other | Influenza | Infections and infestations | Double Blind Placebo | 3 | 143 | 3 |
| other | Influenza | Infections and infestations | Double Blind Benralizumab First, Then Open Label Benralizumab | 4 | 122 | 4 |
| other | Influenza | Infections and infestations | Double Blind Placebo First, Then Open Label Benralizumab | 1 | 125 | 1 |
| other | Nasopharyngitis | Infections and infestations | Double Blind Benralizumab | 11 | 144 | 12 |
| other | Nasopharyngitis | Infections and infestations | Double Blind Placebo | 9 | 143 | 10 |
1 to 10 of 184Source ClinicalTrials.gov
See all 184 adverse eventsAdverse event totals12
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Double Blind Benralizumab | 0 | 144 |
| Total, all-cause mortality | Double Blind Placebo | 0 | 143 |
| Total, all-cause mortality | Double Blind Benralizumab First, Then Open Label Benralizumab | 0 | 122 |
| Total, all-cause mortality | Double Blind Placebo First, Then Open Label Benralizumab | 0 | 125 |
| Total, other adverse events | Double Blind Benralizumab | 78 | 144 |
| Total, other adverse events | Double Blind Placebo | 59 | 143 |
| Total, other adverse events | Double Blind Benralizumab First, Then Open Label Benralizumab | 37 | 122 |
| Total, other adverse events | Double Blind Placebo First, Then Open Label Benralizumab | 33 | 125 |
| Total, serious adverse events | Double Blind Benralizumab | 12 | 144 |
| Total, serious adverse events | Double Blind Placebo | 12 | 143 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse event totalsPapers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 33710614 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons3
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Double Blind Benralizumab vs Double Blind Placebo: Percentage of Participants With Surgery and/or Use SCS for CRSwNP | Trial comparisons |
| Double Blind Benralizumab vs Double Blind Placebo: Percentage of Participants With Surgery for CRSwNP | Trial comparisons |
| Double Blind Benralizumab vs Double Blind Placebo: Percentage of Participants With SCS Use for CRSwNP | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04157335
GET https://conductscience.org/api/trials/v1/NCT04157335/results?page=2